Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G. Loupakis F, et al. Among authors: frumento p. Br J Cancer. 2011 Apr 12;104(8):1262-9. doi: 10.1038/bjc.2011.85. Epub 2011 Mar 15. Br J Cancer. 2011. PMID: 21407216 Free PMC article. Clinical Trial.
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F. Loupakis F, et al. Among authors: frumento p. BMC Cancer. 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247. BMC Cancer. 2011. PMID: 21669012 Free PMC article.
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy.
Sottile R, Tannazi M, Johansson MH, Cristiani CM, Calabró L, Ventura V, Cutaia O, Chiarucci C, Covre A, Garofalo C, Pontén V, Tallerico R, Frumento P, Micke P, Maio M, Kärre K, Carbone E. Sottile R, et al. Among authors: frumento p. Int J Cancer. 2019 Oct 15;145(8):2238-2248. doi: 10.1002/ijc.32363. Epub 2019 May 13. Int J Cancer. 2019. PMID: 31018250 Free article.
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression.
Crea F, Quagliata L, Michael A, Liu HH, Frumento P, Azad AA, Xue H, Pikor L, Watahiki A, Morant R, Eppenberger-Castori S, Wang Y, Parolia A, Lennox KA, Lam WL, Gleave M, Chi KN, Pandha H, Wang Y, Helgason CD. Crea F, et al. Among authors: frumento p. Mol Oncol. 2016 May;10(5):693-703. doi: 10.1016/j.molonc.2015.12.010. Epub 2015 Dec 22. Mol Oncol. 2016. PMID: 26809501 Free PMC article.
Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies.
Carrasquilla GD, Frumento P, Berglund A, Borgfeldt C, Bottai M, Chiavenna C, Eliasson M, Engström G, Hallmans G, Jansson JH, Magnusson PK, Nilsson PM, Pedersen NL, Wolk A, Leander K. Carrasquilla GD, et al. Among authors: frumento p. PLoS Med. 2017 Nov 17;14(11):e1002445. doi: 10.1371/journal.pmed.1002445. eCollection 2017 Nov. PLoS Med. 2017. PMID: 29149179 Free PMC article.
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.
Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E. Tallerico R, et al. Among authors: frumento p. Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242. eCollection 2017. Oncoimmunology. 2016. PMID: 28344869 Free PMC article.
82 results